

Blood Initiative Update

Thank you to all of the Centers who are sending in blood samples as part of the ADGC and NCRAD blood sample initiative! There are now 14 Centers that are sending blood samples to NCRAD as part of this effort and we hope to see that continue to grow.

	Blood samples from new subjects
Arizona	239
Boston U	4
Emory	14
Johns Hopkins	43
Mount Sinai	196
New York U	186
Oregon Health & Science U	55
U California, Irvine	107
U California, San Diego	57
U California, San Francisco	12
U Kentucky	71
U Pennsylvania	81
U Pittsburgh	157
Washington U, St. Louis	466
Total	1688

*counts as of 8/8/2013

ADSP-Alzheimer's Disease Sequencing Project

The first phase of the ADSP focused on whole genome sequencing of 582 subjects from families having many late onset AD family members. Sequencing is well underway and will be completed by the end of the year.

The second phase of the ADSP is now focused on whole exome sequencing of 5,000 cases, 5,000 controls and ~1,000 cases from multiplex families. As

Please contact us with any questions or concerns about NCRAD at 800-526-2839/317-274-7360, by email at kelfaber@iu.edu or visit our web-site: www.ncrad.org Thanks!!

of the first of August, over 10,600 samples have been shipped to the three Large Scale Sequencing Centers (LSSCs). Among those are 3,270 samples from the ADCs sent to NCRAD. Thank you to all of the Centers who rapidly sent replacement samples to NCRAD as needed!

The LSSCs are now performing quality control checks on all of the samples and have begun whole exome sequencing.

Replacement Samples

Because of all the studies performed using ADC samples provided as part of the ADGC initiatives, NCRAD has depleted or nearly depleted many of our samples. In order to continue to provide ADC samples for additional valuable ADGC and ADSP projects, it is vital for NCRAD to obtain additional DNA for many subjects.

While we are delighted to receive any sample type for these subjects, we realize that Centers can often only send limited amounts of extracted DNA. Therefore, we would like to encourage sites to send in brain tissue or blood samples for subjects that have previously had a DNA submitted to NCRAD. By sending in additional samples proactively, it will ensure that these subjects remain eligible for future initiatives and reduce the scramble to replace or replenish samples as new projects begin. These replacement samples will not be eligible for ADGC reimbursement. However, when brain or blood samples are shipped to NCRAD as part of any NACC list, NCRAD will return 25ug of DNA back to the site free of charge and cover the cost of shipping.

A Central Repository with DNA available to match the rich dataset collected for all subjects seen in the ADCs is a very valuable resource for the field of Alzheimer's disease. We hope that you will continue to support this effort!

NIAGADS is a National Genetics Data Repository that facilitates access to genotype data to qualified investigators for the study of the genetics of late-onset Alzheimer's disease. It is the policy of the NIA that all genetic data derived from NIA-funded studies for the genetics of late-onset Alzheimer's disease should be deposited at NIAGADS, another NIA-approved site, or both. NIAGADS, along with other NIA-approved sites, will make these genetic data and associated phenotypic data available to qualified investigators in the scientific community for secondary analysis.

New Datasets Available Through NIAGADS

ROSMAP (NG00029)

<u>Subjects</u>	<u>Markers</u>
MAP: 891	750,173
ROS: 804	
Total: 1,695	

Phenotypes
Sex, PrevAD, IncAD, Age at Onset, Age Base, APOE, Autopsy, BRAAK, Race, Ethnicity

TGEN II (NG00028)

<u>Subjects</u>	<u>Markers</u>
Cases: 1,014	750,173
Controls: 585	
Total: 1,599	

Phenotypes
AD, APOE, Gender, Age at Death, CERAD, BRAAK, Age at Onset

► For more information, visit <http://www.niagads.org>.